menu
    • menu
    [{"orgOrder":0,"company":"St. Anna Kinderkrebsforschung","sponsor":"ALL SCTped Forum | European Society for Blood and Marrow Transplantation | ALL-BFM Study Group | Assistance Publique \u2013 H\u00f4pitaux de Paris | Dutch Childhood Oncology Group | Swiss Pediatric Oncology Group | Australian & New Zealand Children's Haematology\/On","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Thiotepa","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"St. Anna Kinderkrebsforschung","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Anna Kinderkrebsforschung \/ ALL SCTped Forum | European Society for Blood and Marrow Transplantation | ALL-BFM Study Group | Assistance Publique \u2013 H\u00f4pitaux de Paris | Dutch Childhood Oncology Group | Swiss Pediatric Oncology Group | Australian & New Zealand Children's Haematology\/On","highestDevelopmentStatusID":"9","companyTruncated":"St. Anna Kinderkrebsforschung \/ ALL SCTped Forum | European Society for Blood and Marrow Transplantation | ALL-BFM Study Group | Assistance Publique \u2013 H\u00f4pitaux de Paris | Dutch Childhood Oncology Group | Swiss Pediatric Oncology Group | Australian & New Zealand Children's Haematology\/On"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Thiotepa","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shorla Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Thiotepa","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shorla Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Thiotepa","moa":"DNA","graph1":"Hematology","graph2":"Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baptist Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baptist Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Thiotepa

    Menu

    Thiotepa

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shorla Oncology

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shorla Oncology

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shorla Gets FDA Nod for TEPYLUTE Vials to Treat Breast, Ovarian Cancer

                            Details : Tepylute, a ready-to-dilute formulation of thiotepa to treat breast and ovarian cancer, that eliminates the need for reconstitution.

                            Product Name : Tepylute

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2025

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shorla Oncology

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shorla Oncology

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shorla Oncology Gets FDA Approval for TEPYLUTE for Breast and Ovarian Cancer

                            Details : FDA has approved the NDA for alkylating agent, TEPYLUTE (thiotepa), a ready-to-dilute infusion formulation to treat breast and ovarian cancer.

                            Product Name : Tepylute

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2024

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Baptist Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Baptist Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

                            Details : Thiotepa is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hematologic Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 24, 2020

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            St. Anna Kinderkrebsforschung

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            St. Anna Kinderkrebsforschung

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : ALL SCTped Forum | European Society for Blood and Marrow Transplantation | ALL-BFM Study Group | Assistance Publique – Hôpitaux de Paris | Dutch Childhood Oncology Group | Swiss Pediatric Oncology Group | Australian & New Zealand Children's Haematology/On

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

                            Details : Thiotepa is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2013

                            Lead Product(s) : Thiotepa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : ALL SCTped Forum | European Society for Blood and Marrow Transplantation | ALL-BFM Study Group | Assistance Publique – Hôpitaux de Paris | Dutch Childhood Oncology Group | Swiss Pediatric Oncology Group | Australian & New Zealand Children's Haematology/On

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth